Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 1(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02475876Phase 1Completed

PK of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children

Role: lead

NCT01994993Phase 2Completed

Antibiotic Safety (SCAMP)

Role: lead

NCT01169402Phase 1Completed

Pharmacokinetics/Pharmacodynamics (PK/PD) of Fluconazole in Children on Extracorporeal Membrane Oxygenation (ECMO)

Role: lead

NCT01222585Phase 1Completed

Metronidazole Pharmacokinetics (PK) in Premature Infants

Role: lead

NCT00734500Phase 1Completed

Anidulafungin PK in Infants and Toddlers

Role: lead

All 5 trials loaded